{
  "model": "glm-5",
  "taskId": "tumor-vaccine-ici",
  "runIndex": 1,
  "result": {
    "text": "All four required output files have been written successfully and contain valid JSON conforming to their respective schemas.\n\n## Completion Checklist\n\n| Output File | Schema | Status |\n|------------|--------|--------|\n| `output/study_overview.json` | `schemas/study_overview.schema.json` | ✓ Written |\n| `output/quantitative_findings.json` | `schemas/quantitative_findings.schema.json` | ✓ Written |\n| `output/claim_audit.json` | `schemas/claim_audit.schema.json` | ✓ Written |\n| `output/public_summary.json` | `schemas/public_summary.schema.json` | ✓ Written |",
    "thoughts": "",
    "steps": [
      {
        "step": 1,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "TASK.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Agent Task\nL2: \nL3: Task id: tumor-vaccine-ici\nL4: Task title: mRNA tumor sensitization for checkpoint blockade\nL5: Reference paper: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL6: Reference URL: https://www.nature.com/articles/s41586-025-09006-8\nL7: \nL8: ## Objective\nL9: Read the report and produce all required JSON outputs that satisfy their schemas.\nL10: \nL11: ## Inputs On Disk\nL12: - Report: `input/report.md`\nL13: - Schemas: in `schemas/`\nL14: \nL15: ## Required Outputs\nL16: - `output/study_overview.json` (schema: `schemas/study_overview.schema.json`)\nL17: - `output/quantitative_findings.json` (schema: `schemas/quantitative_findings.schema.json`)\nL18: - `output/claim_audit.json` (schema: `schemas/claim_audit.schema.json`)\nL19: - `output/public_summary.json` (schema: `schemas/public_summary.schema.json`)\nL20: \nL21: ## Constraints\nL22: - Do not invent source facts; derive calculations only from values in the report.\nL23: - Use line refs as `L<number>` where required.\nL24: - Where quotes are required, copy exact report snippets.\nL25: - For calculation outputs, line_refs must include every report line used for equations, constants, and numeric substitutions.\nL26: - Use relative paths only.\nL27: - Never use absolute paths.\nL28: - Never use `..` in paths.\nL29: - Write valid JSON only.\nL30: \nL31: ## Completion\nL32: Respond with a checklist of written output files.\nL33: After the checklist, stop. Do not call more tools.",
            "callId": "chatcmpl-tool-a44f19f10f669150"
          }
        ],
        "usage": {
          "promptTokens": 1175,
          "cachedTokens": 0,
          "responseTokens": 55,
          "totalTokens": 1230
        },
        "costUsd": 0.001351
      },
      {
        "step": 2,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "input/report.md",
              "offset": null,
              "limit": null
            },
            "output": "L1: # Structured Paper Report: Tumor Sensitization by mRNA Vaccination\nL2: \nL3: ## Citation\nL4: - Title: SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\nL5: - Journal: Nature\nL6: - Year: 2025\nL7: - DOI: 10.1038/s41586-025-09006-8\nL8: - Source URL: https://www.nature.com/articles/s41586-025-09006-8\nL9: \nL10: ## One-Paragraph Context\nL11: Immune checkpoint inhibitors (ICIs) can produce durable responses in some cancers, but many tumors remain non-responsive due to weak antigen presentation or poor immune priming. The paper investigates whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy.\nL12: \nL13: ## Study Design Snapshot\nL14: - Preclinical arm: multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations.\nL15: - Translational arm: a retrospective cohort of metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status.\nL16: - Mechanistic probes: immunopeptidomics, transcriptomics, and perturbation controls (including IFNAR1 blockade and non-mRNA particle controls).\nL17: \nL18: ## Cohorts and Scenarios\nL19: 1. Mouse efficacy cohort (combination therapy): 78 tumor-bearing mice pooled across repeat experiments.\nL20: 2. Mouse control cohort (vaccine only, ICI only, and vehicle): 84 tumor-bearing mice pooled across matched controls.\nL21: 3. Human retrospective metastatic cohort: 130 patients total.\nL22: 4. Human vaccinated subgroup: 43 patients.\nL23: 5. Human unvaccinated subgroup: 87 patients.\nL24: \nL25: ## Quantitative Findings\nL26: | Metric | Vaccine/Combination Arm | Comparator | Interpretation |\nL27: |---|---:|---:|---|\nL28: | Fraction of tumor proteins represented in immunopeptidome | 62.3% | 37.3% | Broader antigen display after intratumoral mRNA vaccination |\nL29: | Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape |\nL30: | Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment |\nL31: | Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors |\nL32: | PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable |\nL33: | Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy |\nL34: \nL35: ## Controls and Null/Conditional Results\nL36: - Vaccine-only treatment did not produce durable tumor control in non-immunogenic models.\nL37: - ICI-only treatment had limited activity in low-immunogenic baseline settings.\nL38: - Lipid particle controls lacking mRNA did not reproduce the sensitization effect.\nL39: - Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit.\nL40: \nL41: ## Mechanistic Chain Proposed by Authors\nL42: 1. Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling.\nL43: 2. Interferon-associated antigen processing and presentation pathways increase.\nL44: 3. A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells.\nL45: 4. PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade.\nL46: 5. Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort.\nL47: \nL48: ## Caveats and Threats to Validity\nL49: - The human analysis is retrospective and non-randomized; residual confounding is likely.\nL50: - Vaccination timing relative to ICI initiation varied across patients.\nL51: - Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation.\nL52: - Mouse model effects may not map one-to-one to all human tumors.\nL53: - Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings.\nL54: \nL55: ## Practical Takeaway\nL56: The study supports a biologically coherent hypothesis that intratumoral mRNA vaccination can prime tumors for stronger ICI responses, but prospective randomized studies are required before clinical protocol changes are justified.",
            "callId": "chatcmpl-tool-b60da585f120811e"
          },
          {
            "toolName": "list_directory",
            "input": {
              "dir_path": "schemas",
              "ignore": null,
              "file_filtering_options": null
            },
            "output": "claim_audit.schema.json\npublic_summary.schema.json\nquantitative_findings.schema.json\nstudy_overview.schema.json",
            "callId": "chatcmpl-tool-a4a061aebf21f7b7"
          }
        ],
        "usage": {
          "promptTokens": 1615,
          "cachedTokens": 0,
          "responseTokens": 84,
          "totalTokens": 1699
        },
        "costUsd": 0.0018838
      },
      {
        "step": 3,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/study_overview.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-study_overview\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"paper\": {\nL7:       \"type\": \"object\",\nL8:       \"properties\": {\nL9:         \"title\": {\nL10:           \"type\": \"string\",\nL11:           \"minLength\": 10\nL12:         },\nL13:         \"doi\": {\nL14:           \"type\": \"string\",\nL15:           \"pattern\": \"^10\\\\.\"\nL16:         },\nL17:         \"publication_year\": {\nL18:           \"type\": \"integer\",\nL19:           \"minimum\": 1900,\nL20:           \"maximum\": 2100\nL21:         },\nL22:         \"domain\": {\nL23:           \"type\": \"string\",\nL24:           \"enum\": [\nL25:             \"oncology-immunology\",\nL26:             \"exoplanet-atmospheres\",\nL27:             \"climate-science\",\nL28:             \"neuroscience\",\nL29:             \"other\"\nL30:           ]\nL31:         },\nL32:         \"study_type\": {\nL33:           \"type\": \"string\",\nL34:           \"enum\": [\nL35:             \"preclinical+retrospective\",\nL36:             \"observational-astronomy\",\nL37:             \"randomized-trial\",\nL38:             \"simulation\",\nL39:             \"mixed\"\nL40:           ]\nL41:         }\nL42:       },\nL43:       \"required\": [\nL44:         \"title\",\nL45:         \"doi\",\nL46:         \"publication_year\",\nL47:         \"domain\",\nL48:         \"study_type\"\nL49:       ],\nL50:       \"additionalProperties\": false\nL51:     },\nL52:     \"core_question\": {\nL53:       \"type\": \"string\",\nL54:       \"minLength\": 20\nL55:     },\nL56:     \"datasets_or_cohorts\": {\nL57:       \"type\": \"array\",\nL58:       \"items\": {\nL59:         \"type\": \"object\",\nL60:         \"properties\": {\nL61:           \"id\": {\nL62:             \"type\": \"string\",\nL63:             \"pattern\": \"^[a-z0-9-]+$\"\nL64:           },\nL65:           \"label\": {\nL66:             \"type\": \"string\",\nL67:             \"minLength\": 3\nL68:           },\nL69:           \"sample_size_or_observations\": {\nL70:             \"type\": \"string\",\nL71:             \"minLength\": 1\nL72:           },\nL73:           \"description\": {\nL74:             \"type\": \"string\",\nL75:             \"minLength\": 20\nL76:           }\nL77:         },\nL78:         \"required\": [\nL79:           \"id\",\nL80:           \"label\",\nL81:           \"sample_size_or_observations\",\nL82:           \"description\"\nL83:         ],\nL84:         \"additionalProperties\": false\nL85:       },\nL86:       \"minItems\": 2,\nL87:       \"maxItems\": 8\nL88:     },\nL89:     \"major_limitations\": {\nL90:       \"type\": \"array\",\nL91:       \"items\": {\nL92:         \"type\": \"string\",\nL93:         \"minLength\": 12\nL94:       },\nL95:       \"minItems\": 3,\nL96:       \"maxItems\": 8\nL97:     }\nL98:   },\nL99:   \"required\": [\nL100:     \"paper\",\nL101:     \"core_question\",\nL102:     \"datasets_or_cohorts\",\nL103:     \"major_limitations\"\nL104:   ],\nL105:   \"additionalProperties\": false\nL106: }",
            "callId": "chatcmpl-tool-bea0e88dabce1e57"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/quantitative_findings.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-quantitative_findings\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"findings\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^Q[0-9]{2}$\"\nL14:           },\nL15:           \"metric\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 6\nL18:           },\nL19:           \"value\": {\nL20:             \"type\": \"string\",\nL21:             \"minLength\": 1\nL22:           },\nL23:           \"comparator_or_baseline\": {\nL24:             \"type\": \"string\",\nL25:             \"minLength\": 1\nL26:           },\nL27:           \"interpretation\": {\nL28:             \"type\": \"string\",\nL29:             \"minLength\": 12\nL30:           },\nL31:           \"evidence_line_refs\": {\nL32:             \"type\": \"array\",\nL33:             \"items\": {\nL34:               \"type\": \"string\",\nL35:               \"pattern\": \"^L[1-9]\\\\d*$\"\nL36:             },\nL37:             \"minItems\": 1,\nL38:             \"maxItems\": 3\nL39:           }\nL40:         },\nL41:         \"required\": [\nL42:           \"id\",\nL43:           \"metric\",\nL44:           \"value\",\nL45:           \"comparator_or_baseline\",\nL46:           \"interpretation\",\nL47:           \"evidence_line_refs\"\nL48:         ],\nL49:         \"additionalProperties\": false\nL50:       },\nL51:       \"minItems\": 5,\nL52:       \"maxItems\": 14\nL53:     },\nL54:     \"controls_or_null_results\": {\nL55:       \"type\": \"array\",\nL56:       \"items\": {\nL57:         \"type\": \"object\",\nL58:         \"properties\": {\nL59:           \"statement\": {\nL60:             \"type\": \"string\",\nL61:             \"minLength\": 10\nL62:           },\nL63:           \"evidence_line_ref\": {\nL64:             \"$ref\": \"#/definitions/schemas-quantitative_findings/properties/findings/items/properties/evidence_line_refs/items\"\nL65:           }\nL66:         },\nL67:         \"required\": [\nL68:           \"statement\",\nL69:           \"evidence_line_ref\"\nL70:         ],\nL71:         \"additionalProperties\": false\nL72:       },\nL73:       \"minItems\": 2,\nL74:       \"maxItems\": 10\nL75:     }\nL76:   },\nL77:   \"required\": [\nL78:     \"findings\",\nL79:     \"controls_or_null_results\"\nL80:   ],\nL81:   \"additionalProperties\": false\nL82: }",
            "callId": "chatcmpl-tool-b8ab9eacba3ea706"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/claim_audit.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-claim_audit\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"claims\": {\nL7:       \"type\": \"array\",\nL8:       \"items\": {\nL9:         \"type\": \"object\",\nL10:         \"properties\": {\nL11:           \"claim_id\": {\nL12:             \"type\": \"string\",\nL13:             \"pattern\": \"^C[0-9]{2}$\"\nL14:           },\nL15:           \"claim\": {\nL16:             \"type\": \"string\",\nL17:             \"minLength\": 20\nL18:           },\nL19:           \"strength\": {\nL20:             \"type\": \"string\",\nL21:             \"enum\": [\nL22:               \"strong\",\nL23:               \"moderate\",\nL24:               \"tentative\"\nL25:             ]\nL26:           },\nL27:           \"evidence\": {\nL28:             \"type\": \"array\",\nL29:             \"items\": {\nL30:               \"type\": \"object\",\nL31:               \"properties\": {\nL32:                 \"quote\": {\nL33:                   \"type\": \"string\",\nL34:                   \"minLength\": 10\nL35:                 },\nL36:                 \"line_ref\": {\nL37:                   \"type\": \"string\",\nL38:                   \"pattern\": \"^L[1-9]\\\\d*$\"\nL39:                 }\nL40:               },\nL41:               \"required\": [\nL42:                 \"quote\",\nL43:                 \"line_ref\"\nL44:               ],\nL45:               \"additionalProperties\": false\nL46:             },\nL47:             \"minItems\": 2,\nL48:             \"maxItems\": 3\nL49:           },\nL50:           \"caveat\": {\nL51:             \"type\": \"string\",\nL52:             \"minLength\": 20\nL53:           }\nL54:         },\nL55:         \"required\": [\nL56:           \"claim_id\",\nL57:           \"claim\",\nL58:           \"strength\",\nL59:           \"evidence\",\nL60:           \"caveat\"\nL61:         ],\nL62:         \"additionalProperties\": false\nL63:       },\nL64:       \"minItems\": 4,\nL65:       \"maxItems\": 10\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"claims\"\nL70:   ],\nL71:   \"additionalProperties\": false\nL72: }",
            "callId": "chatcmpl-tool-97307a8d6f98567b"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "schemas/public_summary.schema.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"$schema\": \"http://json-schema.org/draft-07/schema#\",\nL3:   \"title\": \"schemas-public_summary\",\nL4:   \"type\": \"object\",\nL5:   \"properties\": {\nL6:     \"headline\": {\nL7:       \"type\": \"string\",\nL8:       \"minLength\": 20,\nL9:       \"maxLength\": 120\nL10:     },\nL11:     \"plain_language_summary\": {\nL12:       \"type\": \"string\",\nL13:       \"minLength\": 180,\nL14:       \"maxLength\": 1200\nL15:     },\nL16:     \"what_is_new\": {\nL17:       \"type\": \"array\",\nL18:       \"items\": {\nL19:         \"type\": \"string\",\nL20:         \"minLength\": 20\nL21:       },\nL22:       \"minItems\": 3,\nL23:       \"maxItems\": 3\nL24:     },\nL25:     \"why_caution_is_needed\": {\nL26:       \"type\": \"array\",\nL27:       \"items\": {\nL28:         \"type\": \"string\",\nL29:         \"minLength\": 20\nL30:       },\nL31:       \"minItems\": 3,\nL32:       \"maxItems\": 5\nL33:     },\nL34:     \"glossary\": {\nL35:       \"type\": \"array\",\nL36:       \"items\": {\nL37:         \"type\": \"object\",\nL38:         \"properties\": {\nL39:           \"term\": {\nL40:             \"type\": \"string\",\nL41:             \"minLength\": 2\nL42:           },\nL43:           \"definition\": {\nL44:             \"type\": \"string\",\nL45:             \"minLength\": 20,\nL46:             \"maxLength\": 220\nL47:           }\nL48:         },\nL49:         \"required\": [\nL50:           \"term\",\nL51:           \"definition\"\nL52:         ],\nL53:         \"additionalProperties\": false\nL54:       },\nL55:       \"minItems\": 4,\nL56:       \"maxItems\": 8\nL57:     },\nL58:     \"open_questions\": {\nL59:       \"type\": \"array\",\nL60:       \"items\": {\nL61:         \"type\": \"string\",\nL62:         \"minLength\": 20\nL63:       },\nL64:       \"minItems\": 3,\nL65:       \"maxItems\": 6\nL66:     }\nL67:   },\nL68:   \"required\": [\nL69:     \"headline\",\nL70:     \"plain_language_summary\",\nL71:     \"what_is_new\",\nL72:     \"why_caution_is_needed\",\nL73:     \"glossary\",\nL74:     \"open_questions\"\nL75:   ],\nL76:   \"additionalProperties\": false\nL77: }",
            "callId": "chatcmpl-tool-813aeb8a4ebe7955"
          }
        ],
        "usage": {
          "promptTokens": 2764,
          "cachedTokens": 0,
          "responseTokens": 146,
          "totalTokens": 2910
        },
        "costUsd": 0.0032312
      },
      {
        "step": 4,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "Now I'll write all four required output files based on the report and schemas.",
        "toolCalls": [
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/study_overview.json",
              "content": "{\n  \"paper\": {\n    \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\n    \"doi\": \"10.1038/s41586-025-09006-8\",\n    \"publication_year\": 2025,\n    \"domain\": \"oncology-immunology\",\n    \"study_type\": \"preclinical+retrospective\"\n  },\n  \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy\",\n  \"datasets_or_cohorts\": [\n    {\n      \"id\": \"mouse-efficacy-cohort\",\n      \"label\": \"Mouse efficacy cohort (combination therapy)\",\n      \"sample_size_or_observations\": \"78 tumor-bearing mice\",\n      \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments\"\n    },\n    {\n      \"id\": \"mouse-control-cohort\",\n      \"label\": \"Mouse control cohort\",\n      \"sample_size_or_observations\": \"84 tumor-bearing mice\",\n      \"description\": \"Vaccine only, ICI only, and vehicle control groups pooled across matched controls\"\n    },\n    {\n      \"id\": \"human-metastatic-cohort\",\n      \"label\": \"Human retrospective metastatic cohort\",\n      \"sample_size_or_observations\": \"130 patients\",\n      \"description\": \"Metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status\"\n    },\n    {\n      \"id\": \"human-vaccinated-subgroup\",\n      \"label\": \"Human vaccinated subgroup\",\n      \"sample_size_or_observations\": \"43 patients\",\n      \"description\": \"Patients from the retrospective cohort who had prior SARS-CoV-2 mRNA vaccination\"\n    },\n    {\n      \"id\": \"human-unvaccinated-subgroup\",\n      \"label\": \"Human unvaccinated subgroup\",\n      \"sample_size_or_observations\": \"87 patients\",\n      \"description\": \"Patients from the retrospective cohort without prior SARS-CoV-2 mRNA vaccination\"\n    }\n  ],\n  \"major_limitations\": [\n    \"The human analysis is retrospective and non-randomized; residual confounding is likely\",\n    \"Vaccination timing relative to ICI initiation varied across patients\",\n    \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation\",\n    \"Mouse model effects may not map one-to-one to all human tumors\",\n    \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/study_overview.json",
            "callId": "chatcmpl-tool-9730fb31423e736c"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "content": "{\n  \"findings\": [\n    {\n      \"id\": \"Q01\",\n      \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\n      \"value\": \"62.3%\",\n      \"comparator_or_baseline\": \"37.3%\",\n      \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\n      \"evidence_line_refs\": [\"L28\"]\n    },\n    {\n      \"id\": \"Q02\",\n      \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\n      \"value\": \"40.6%\",\n      \"comparator_or_baseline\": \"20.6%\",\n      \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\n      \"evidence_line_refs\": [\"L29\"]\n    },\n    {\n      \"id\": \"Q03\",\n      \"metric\": \"Retrospective human survival comparison p-value\",\n      \"value\": \"p=0.01\",\n      \"comparator_or_baseline\": \"N/A\",\n      \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\n      \"evidence_line_refs\": [\"L30\"]\n    },\n    {\n      \"id\": \"Q04\",\n      \"metric\": \"Type I interferon response score (normalized units)\",\n      \"value\": \"3.1\",\n      \"comparator_or_baseline\": \"1.0\",\n      \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\n      \"evidence_line_refs\": [\"L31\"]\n    },\n    {\n      \"id\": \"Q05\",\n      \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\n      \"value\": \"2.4x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Checkpoint axis became more targetable\",\n      \"evidence_line_refs\": [\"L32\"]\n    },\n    {\n      \"id\": \"Q06\",\n      \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\n      \"value\": \"1.8x\",\n      \"comparator_or_baseline\": \"1.0x\",\n      \"interpretation\": \"Increased immune infiltration with combination therapy\",\n      \"evidence_line_refs\": [\"L33\"]\n    }\n  ],\n  \"controls_or_null_results\": [\n    {\n      \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models\",\n      \"evidence_line_ref\": \"L36\"\n    },\n    {\n      \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings\",\n      \"evidence_line_ref\": \"L37\"\n    },\n    {\n      \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect\",\n      \"evidence_line_ref\": \"L38\"\n    },\n    {\n      \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit\",\n      \"evidence_line_ref\": \"L39\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/quantitative_findings.json",
            "callId": "chatcmpl-tool-a0e21c1185483574"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "content": "{\n  \"claims\": [\n    {\n      \"claim_id\": \"C01\",\n      \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling\",\n          \"line_ref\": \"L42\"\n        },\n        {\n          \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\n          \"line_ref\": \"L31\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\n    },\n    {\n      \"claim_id\": \"C02\",\n      \"claim\": \"A broader peptide repertoire appears on MHC-I after mRNA vaccination, improving tumor visibility to T cells\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells\",\n          \"line_ref\": \"L44\"\n        },\n        {\n          \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\n          \"line_ref\": \"L29\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors\"\n    },\n    {\n      \"claim_id\": \"C03\",\n      \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mice\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort\",\n          \"line_ref\": \"L46\"\n        },\n        {\n          \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\n          \"line_ref\": \"L33\"\n        }\n      ],\n      \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors\"\n    },\n    {\n      \"claim_id\": \"C04\",\n      \"claim\": \"Vaccinated patients had improved survival under ICI treatment compared to unvaccinated patients\",\n      \"strength\": \"moderate\",\n      \"evidence\": [\n        {\n          \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\n          \"line_ref\": \"L30\"\n        },\n        {\n          \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort\",\n          \"line_ref\": \"L46\"\n        }\n      ],\n      \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients\"\n    },\n    {\n      \"claim_id\": \"C05\",\n      \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade\",\n      \"strength\": \"strong\",\n      \"evidence\": [\n        {\n          \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade\",\n          \"line_ref\": \"L45\"\n        },\n        {\n          \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\n          \"line_ref\": \"L32\"\n        }\n      ],\n      \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\n    }\n  ]\n}"
            },
            "output": "Successfully wrote file: output/claim_audit.json",
            "callId": "chatcmpl-tool-a8236c3ade667625"
          },
          {
            "toolName": "write_file",
            "input": {
              "file_path": "output/public_summary.json",
              "content": "{\n  \"headline\": \"mRNA vaccines may help immunotherapy drugs work better against tumors, early study suggests\",\n  \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, similar to those used for COVID-19, could make cancer tumors more vulnerable to immunotherapy drugs. Immunotherapy helps the immune system fight cancer, but it does not work for everyone. In mice with tumors, injecting an mRNA vaccine directly into the tumor made the cancer more visible to immune cells and increased the levels of a protein called PD-L1, which is the target of many immunotherapy drugs. When researchers combined the mRNA vaccine with an immunotherapy drug, tumors were better controlled. They also looked at medical records from 130 patients with metastatic cancer who received immunotherapy. Patients who had been vaccinated against COVID-19 with an mRNA vaccine before their cancer treatment seemed to survive longer than unvaccinated patients. However, this finding comes from looking back at existing records rather than a controlled experiment, so more research is needed.\",\n  \"what_is_new\": [\n    \"The study tested injecting mRNA vaccines directly into tumors to boost immune response against cancer\",\n    \"Combining mRNA vaccines with immunotherapy drugs improved tumor control in mouse models\",\n    \"Patients previously vaccinated with mRNA COVID-19 vaccines showed better outcomes when treated with immunotherapy\"\n  ],\n  \"why_caution_is_needed\": [\n    \"The human data came from reviewing past medical records, not from a controlled clinical trial\",\n    \"The timing between vaccination and cancer treatment varied among patients\",\n    \"Results from mouse studies may not apply the same way to human cancers\",\n    \"Different types of cancer and previous treatments may affect outcomes in ways not captured by this study\",\n    \"Prospective randomized studies are required before clinical protocol changes are justified\"\n  ],\n  \"glossary\": [\n    {\n      \"term\": \"Immune checkpoint inhibitor (ICI)\",\n      \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by removing the 'brakes' that tumors use to hide from immune attack\"\n    },\n    {\n      \"term\": \"PD-L1\",\n      \"definition\": \"A protein found on the surface of some cells, including cancer cells, that can turn off immune responses; it is a target for some immunotherapy drugs\"\n    },\n    {\n      \"term\": \"mRNA vaccine\",\n      \"definition\": \"A vaccine that uses messenger RNA to instruct cells to make a protein that triggers an immune response, teaching the body how to fight a future infection or disease\"\n    },\n    {\n      \"term\": \"MHC-I\",\n      \"definition\": \"A molecule on the surface of cells that displays small pieces of proteins, allowing immune cells to inspect what is happening inside the cell and detect abnormalities\"\n    },\n    {\n      \"term\": \"CD8+ T cells\",\n      \"definition\": \"A type of white blood cell that can directly kill infected or cancerous cells; they are often called 'killer T cells' and are important for anti-tumor immunity\"\n    },\n    {\n      \"term\": \"Type I interferon\",\n      \"definition\": \"A signaling protein produced by cells in response to viruses and other threats; it helps activate immune responses and can make tumors more visible to the immune system\"\n    },\n    {\n      \"term\": \"Retrospective study\",\n      \"definition\": \"A research study that looks backward at existing data, such as medical records, rather than following patients forward in time from a defined starting point\"\n    },\n    {\n      \"term\": \"Antigen presentation\",\n      \"definition\": \"The process by which cells display fragments of proteins on their surface for immune cells to inspect, allowing the immune system to detect infected or cancerous cells\"\n    }\n  ],\n  \"open_questions\": [\n    \"Will these findings hold up in prospective randomized clinical trials in humans?\",\n    \"What is the optimal timing between mRNA vaccination and starting immunotherapy?\",\n    \"Which types of cancer are most likely to benefit from this approach?\",\n    \"What is the best mRNA formulation for tumor sensitization?\",\n    \"How long does the sensitization effect from mRNA vaccination last?\",\n    \"Can systemic mRNA vaccination produce similar effects, or must it be injected into the tumor?\"\n  ]\n}"
            },
            "output": "Successfully wrote file: output/public_summary.json",
            "callId": "chatcmpl-tool-999394a608241ad7"
          }
        ],
        "usage": {
          "promptTokens": 5799,
          "cachedTokens": 0,
          "responseTokens": 4087,
          "totalTokens": 9886
        },
        "costUsd": 0.0188774
      },
      {
        "step": 5,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "toolCalls": [
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/study_overview.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"paper\": {\nL3:     \"title\": \"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade\",\nL4:     \"doi\": \"10.1038/s41586-025-09006-8\",\nL5:     \"publication_year\": 2025,\nL6:     \"domain\": \"oncology-immunology\",\nL7:     \"study_type\": \"preclinical+retrospective\"\nL8:   },\nL9:   \"core_question\": \"Whether intratumoral delivery of an mRNA vaccine can create an interferon-rich inflammatory state that improves sensitivity to anti-PD-L1 therapy\",\nL10:   \"datasets_or_cohorts\": [\nL11:     {\nL12:       \"id\": \"mouse-efficacy-cohort\",\nL13:       \"label\": \"Mouse efficacy cohort (combination therapy)\",\nL14:       \"sample_size_or_observations\": \"78 tumor-bearing mice\",\nL15:       \"description\": \"Multiple murine tumor models with intratumoral mRNA vaccine and anti-PD-L1 combinations, pooled across repeat experiments\"\nL16:     },\nL17:     {\nL18:       \"id\": \"mouse-control-cohort\",\nL19:       \"label\": \"Mouse control cohort\",\nL20:       \"sample_size_or_observations\": \"84 tumor-bearing mice\",\nL21:       \"description\": \"Vaccine only, ICI only, and vehicle control groups pooled across matched controls\"\nL22:     },\nL23:     {\nL24:       \"id\": \"human-metastatic-cohort\",\nL25:       \"label\": \"Human retrospective metastatic cohort\",\nL26:       \"sample_size_or_observations\": \"130 patients\",\nL27:       \"description\": \"Metastatic patients receiving ICI treatment, compared by prior SARS-CoV-2 mRNA vaccination status\"\nL28:     },\nL29:     {\nL30:       \"id\": \"human-vaccinated-subgroup\",\nL31:       \"label\": \"Human vaccinated subgroup\",\nL32:       \"sample_size_or_observations\": \"43 patients\",\nL33:       \"description\": \"Patients from the retrospective cohort who had prior SARS-CoV-2 mRNA vaccination\"\nL34:     },\nL35:     {\nL36:       \"id\": \"human-unvaccinated-subgroup\",\nL37:       \"label\": \"Human unvaccinated subgroup\",\nL38:       \"sample_size_or_observations\": \"87 patients\",\nL39:       \"description\": \"Patients from the retrospective cohort without prior SARS-CoV-2 mRNA vaccination\"\nL40:     }\nL41:   ],\nL42:   \"major_limitations\": [\nL43:     \"The human analysis is retrospective and non-randomized; residual confounding is likely\",\nL44:     \"Vaccination timing relative to ICI initiation varied across patients\",\nL45:     \"Tumor-type mix and treatment-history heterogeneity limit direct causal interpretation\",\nL46:     \"Mouse model effects may not map one-to-one to all human tumors\",\nL47:     \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\nL48:   ]\nL49: }",
            "callId": "chatcmpl-tool-b3eddf2ca57a0f7c"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/quantitative_findings.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"findings\": [\nL3:     {\nL4:       \"id\": \"Q01\",\nL5:       \"metric\": \"Fraction of tumor proteins represented in immunopeptidome\",\nL6:       \"value\": \"62.3%\",\nL7:       \"comparator_or_baseline\": \"37.3%\",\nL8:       \"interpretation\": \"Broader antigen display after intratumoral mRNA vaccination\",\nL9:       \"evidence_line_refs\": [\"L28\"]\nL10:     },\nL11:     {\nL12:       \"id\": \"Q02\",\nL13:       \"metric\": \"Fraction of proteins represented in MHC-I peptidome\",\nL14:       \"value\": \"40.6%\",\nL15:       \"comparator_or_baseline\": \"20.6%\",\nL16:       \"interpretation\": \"Strong expansion of MHC-I-presented landscape\",\nL17:       \"evidence_line_refs\": [\"L29\"]\nL18:     },\nL19:     {\nL20:       \"id\": \"Q03\",\nL21:       \"metric\": \"Retrospective human survival comparison p-value\",\nL22:       \"value\": \"p=0.01\",\nL23:       \"comparator_or_baseline\": \"N/A\",\nL24:       \"interpretation\": \"Vaccinated subgroup had improved survival under ICI treatment\",\nL25:       \"evidence_line_refs\": [\"L30\"]\nL26:     },\nL27:     {\nL28:       \"id\": \"Q04\",\nL29:       \"metric\": \"Type I interferon response score (normalized units)\",\nL30:       \"value\": \"3.1\",\nL31:       \"comparator_or_baseline\": \"1.0\",\nL32:       \"interpretation\": \"Marked induction after mRNA vaccination in tumors\",\nL33:       \"evidence_line_refs\": [\"L31\"]\nL34:     },\nL35:     {\nL36:       \"id\": \"Q05\",\nL37:       \"metric\": \"PD-L1 expression fold-change in tumor tissue\",\nL38:       \"value\": \"2.4x\",\nL39:       \"comparator_or_baseline\": \"1.0x\",\nL40:       \"interpretation\": \"Checkpoint axis became more targetable\",\nL41:       \"evidence_line_refs\": [\"L32\"]\nL42:     },\nL43:     {\nL44:       \"id\": \"Q06\",\nL45:       \"metric\": \"Intratumoral CD8+ T-cell density fold-change\",\nL46:       \"value\": \"1.8x\",\nL47:       \"comparator_or_baseline\": \"1.0x\",\nL48:       \"interpretation\": \"Increased immune infiltration with combination therapy\",\nL49:       \"evidence_line_refs\": [\"L33\"]\nL50:     }\nL51:   ],\nL52:   \"controls_or_null_results\": [\nL53:     {\nL54:       \"statement\": \"Vaccine-only treatment did not produce durable tumor control in non-immunogenic models\",\nL55:       \"evidence_line_ref\": \"L36\"\nL56:     },\nL57:     {\nL58:       \"statement\": \"ICI-only treatment had limited activity in low-immunogenic baseline settings\",\nL59:       \"evidence_line_ref\": \"L37\"\nL60:     },\nL61:     {\nL62:       \"statement\": \"Lipid particle controls lacking mRNA did not reproduce the sensitization effect\",\nL63:       \"evidence_line_ref\": \"L38\"\nL64:     },\nL65:     {\nL66:       \"statement\": \"Blocking type I interferon signaling with anti-IFNAR1 eliminated the observed sensitization benefit\",\nL67:       \"evidence_line_ref\": \"L39\"\nL68:     }\nL69:   ]\nL70: }",
            "callId": "chatcmpl-tool-92483272dbc2bbbb"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/claim_audit.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"claims\": [\nL3:     {\nL4:       \"claim_id\": \"C01\",\nL5:       \"claim\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling\",\nL6:       \"strength\": \"strong\",\nL7:       \"evidence\": [\nL8:         {\nL9:           \"quote\": \"Intratumoral mRNA vaccination triggers local innate sensing and type I interferon signaling\",\nL10:           \"line_ref\": \"L42\"\nL11:         },\nL12:         {\nL13:           \"quote\": \"Type I interferon response score (normalized units) | 3.1 | 1.0 | Marked induction after mRNA vaccination in tumors\",\nL14:           \"line_ref\": \"L31\"\nL15:         }\nL16:       ],\nL17:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\nL18:     },\nL19:     {\nL20:       \"claim_id\": \"C02\",\nL21:       \"claim\": \"A broader peptide repertoire appears on MHC-I after mRNA vaccination, improving tumor visibility to T cells\",\nL22:       \"strength\": \"strong\",\nL23:       \"evidence\": [\nL24:         {\nL25:           \"quote\": \"A broader peptide repertoire appears on MHC-I, improving tumor visibility to T cells\",\nL26:           \"line_ref\": \"L44\"\nL27:         },\nL28:         {\nL29:           \"quote\": \"Fraction of proteins represented in MHC-I peptidome | 40.6% | 20.6% | Strong expansion of MHC-I-presented landscape\",\nL30:           \"line_ref\": \"L29\"\nL31:         }\nL32:       ],\nL33:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors\"\nL34:     },\nL35:     {\nL36:       \"claim_id\": \"C03\",\nL37:       \"claim\": \"Combined mRNA vaccine and anti-PD-L1 intervention improves tumor control in mice\",\nL38:       \"strength\": \"strong\",\nL39:       \"evidence\": [\nL40:         {\nL41:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort\",\nL42:           \"line_ref\": \"L46\"\nL43:         },\nL44:         {\nL45:           \"quote\": \"Intratumoral CD8+ T-cell density fold-change | 1.8x | 1.0x | Increased immune infiltration with combination therapy\",\nL46:           \"line_ref\": \"L33\"\nL47:         }\nL48:       ],\nL49:       \"caveat\": \"Mouse model effects may not map one-to-one to all human tumors\"\nL50:     },\nL51:     {\nL52:       \"claim_id\": \"C04\",\nL53:       \"claim\": \"Vaccinated patients had improved survival under ICI treatment compared to unvaccinated patients\",\nL54:       \"strength\": \"moderate\",\nL55:       \"evidence\": [\nL56:         {\nL57:           \"quote\": \"Retrospective human survival comparison p-value | p=0.01 | N/A | Vaccinated subgroup had improved survival under ICI treatment\",\nL58:           \"line_ref\": \"L30\"\nL59:         },\nL60:         {\nL61:           \"quote\": \"Combined intervention improves tumor control in mice and aligns with better outcomes in the retrospective human cohort\",\nL62:           \"line_ref\": \"L46\"\nL63:         }\nL64:       ],\nL65:       \"caveat\": \"The human analysis is retrospective and non-randomized; residual confounding is likely, and vaccination timing relative to ICI initiation varied across patients\"\nL66:     },\nL67:     {\nL68:       \"claim_id\": \"C05\",\nL69:       \"claim\": \"PD-L1 pathway activity increases after mRNA vaccination, creating a rationale for combining with checkpoint blockade\",\nL70:       \"strength\": \"strong\",\nL71:       \"evidence\": [\nL72:         {\nL73:           \"quote\": \"PD-L1 pathway activity also increases, creating a rationale for combining with checkpoint blockade\",\nL74:           \"line_ref\": \"L45\"\nL75:         },\nL76:         {\nL77:           \"quote\": \"PD-L1 expression fold-change in tumor tissue | 2.4x | 1.0x | Checkpoint axis became more targetable\",\nL78:           \"line_ref\": \"L32\"\nL79:         }\nL80:       ],\nL81:       \"caveat\": \"Some mechanistic readouts were strongest in specific model systems rather than uniformly across all tested settings\"\nL82:     }\nL83:   ]\nL84: }",
            "callId": "chatcmpl-tool-b8ff3fb057ec73d8"
          },
          {
            "toolName": "read_file",
            "input": {
              "file_path": "output/public_summary.json",
              "offset": null,
              "limit": null
            },
            "output": "L1: {\nL2:   \"headline\": \"mRNA vaccines may help immunotherapy drugs work better against tumors, early study suggests\",\nL3:   \"plain_language_summary\": \"Researchers studied whether mRNA vaccines, similar to those used for COVID-19, could make cancer tumors more vulnerable to immunotherapy drugs. Immunotherapy helps the immune system fight cancer, but it does not work for everyone. In mice with tumors, injecting an mRNA vaccine directly into the tumor made the cancer more visible to immune cells and increased the levels of a protein called PD-L1, which is the target of many immunotherapy drugs. When researchers combin\nL4:   \"what_is_new\": [\nL5:     \"The study tested injecting mRNA vaccines directly into tumors to boost immune response against cancer\",\nL6:     \"Combining mRNA vaccines with immunotherapy drugs improved tumor control in mouse models\",\nL7:     \"Patients previously vaccinated with mRNA COVID-19 vaccines showed better outcomes when treated with immunotherapy\"\nL8:   ],\nL9:   \"why_caution_is_needed\": [\nL10:     \"The human data came from reviewing past medical records, not from a controlled clinical trial\",\nL11:     \"The timing between vaccination and cancer treatment varied among patients\",\nL12:     \"Results from mouse studies may not apply the same way to human cancers\",\nL13:     \"Different types of cancer and previous treatments may affect outcomes in ways not captured by this study\",\nL14:     \"Prospective randomized studies are required before clinical protocol changes are justified\"\nL15:   ],\nL16:   \"glossary\": [\nL17:     {\nL18:       \"term\": \"Immune checkpoint inhibitor (ICI)\",\nL19:       \"definition\": \"A type of cancer drug that helps the immune system recognize and attack cancer cells by removing the 'brakes' that tumors use to hide from immune attack\"\nL20:     },\nL21:     {\nL22:       \"term\": \"PD-L1\",\nL23:       \"definition\": \"A protein found on the surface of some cells, including cancer cells, that can turn off immune responses; it is a target for some immunotherapy drugs\"\nL24:     },\nL25:     {\nL26:       \"term\": \"mRNA vaccine\",\nL27:       \"definition\": \"A vaccine that uses messenger RNA to instruct cells to make a protein that triggers an immune response, teaching the body how to fight a future infection or disease\"\nL28:     },\nL29:     {\nL30:       \"term\": \"MHC-I\",\nL31:       \"definition\": \"A molecule on the surface of cells that displays small pieces of proteins, allowing immune cells to inspect what is happening inside the cell and detect abnormalities\"\nL32:     },\nL33:     {\nL34:       \"term\": \"CD8+ T cells\",\nL35:       \"definition\": \"A type of white blood cell that can directly kill infected or cancerous cells; they are often called 'killer T cells' and are important for anti-tumor immunity\"\nL36:     },\nL37:     {\nL38:       \"term\": \"Type I interferon\",\nL39:       \"definition\": \"A signaling protein produced by cells in response to viruses and other threats; it helps activate immune responses and can make tumors more visible to the immune system\"\nL40:     },\nL41:     {\nL42:       \"term\": \"Retrospective study\",\nL43:       \"definition\": \"A research study that looks backward at existing data, such as medical records, rather than following patients forward in time from a defined starting point\"\nL44:     },\nL45:     {\nL46:       \"term\": \"Antigen presentation\",\nL47:       \"definition\": \"The process by which cells display fragments of proteins on their surface for immune cells to inspect, allowing the immune system to detect infected or cancerous cells\"\nL48:     }\nL49:   ],\nL50:   \"open_questions\": [\nL51:     \"Will these findings hold up in prospective randomized clinical trials in humans?\",\nL52:     \"What is the optimal timing between mRNA vaccination and starting immunotherapy?\",\nL53:     \"Which types of cancer are most likely to benefit from this approach?\",\nL54:     \"What is the best mRNA formulation for tumor sensitization?\",\nL55:     \"How long does the sensitization effect from mRNA vaccination last?\",\nL56:     \"Can systemic mRNA vaccination produce similar effects, or must it be injected into the tumor?\"\nL57:   ]\nL58: }",
            "callId": "chatcmpl-tool-a4df27218f520099"
          }
        ],
        "usage": {
          "promptTokens": 8800,
          "cachedTokens": 0,
          "responseTokens": 141,
          "totalTokens": 8941
        },
        "costUsd": 0.0092512
      },
      {
        "step": 6,
        "modelVersion": "accounts/fireworks/models/glm-5",
        "text": "All four required output files have been written successfully and contain valid JSON conforming to their respective schemas.\n\n## Completion Checklist\n\n| Output File | Schema | Status |\n|------------|--------|--------|\n| `output/study_overview.json` | `schemas/study_overview.schema.json` | ✓ Written |\n| `output/quantitative_findings.json` | `schemas/quantitative_findings.schema.json` | ✓ Written |\n| `output/claim_audit.json` | `schemas/claim_audit.schema.json` | ✓ Written |\n| `output/public_summary.json` | `schemas/public_summary.schema.json` | ✓ Written |",
        "toolCalls": [],
        "usage": {
          "promptTokens": 12475,
          "cachedTokens": 0,
          "responseTokens": 701,
          "totalTokens": 13176
        },
        "costUsd": 0.0147182
      }
    ],
    "totalCostUsd": 0.0493128
  }
}
